The urea breath test market involves H. pylori diagnostic procedures that utilize urea and carbon-13 or carbon-14 isotopes to test for the presence of the bacteria in the stomach and duodenum. The presence of urease enzyme released by H. pylori triggers a chemical reaction that releases carbon dioxide which is measured by a machine. Urea breath tests are non-invasive, highly accurate methods to detect current H. pylori infections and evaluate the effectiveness of eradication therapy. They provide results quicker than invasive procedures such as endoscopy and do not require special preparation or handling of specimens. The increasing incidence of H. pylori infections globally due to poor sanitation and limited access to clean drinking water is a major driver for the market.

The Global Urea Breath Test Market is estimated to be valued at US$ 140.8 Mn in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Urea Breath Test Market Growth are Al Dahra ACX Global Inc., Alfalfa Monegros SL, Anderson Hay & Grain Inc., Bailey Farms, Border Valley, Coaba, Cubeit Hay Company, Glenvar Hay, Green Prairie International, Grupo Osés, Gruppo Carli, Hay USA, Haykingdom Inc., Oregon Hay Products, Inc., Los Venteros SC, M&C Hay, Legal Alfalfa Products Ltd., Riverina (Australia) Pty Ltd, SL Follen Company, and Standlee Hay Company.

The growing prevalence of peptic ulcers and gastric cancer attributed to H. pylori infections is fueling demand for accurate diagnostic tests. Furthermore, increasing screening of high-risk populations such as older adults is boosting market growth.

Technological advancements in isotopic breath testing devices have made them more portable, affordable and user-friendly. Automatic analyzers can deliver results quickly without the need for specialized training or complex specimen handling. This is expected to support wider adoption of urea breath tests in diagnostic labs.

Market Trends

Non-invasive nature of urea breath tests: Their ease of use compared to endoscopy or stool antigen tests is a key factor driving preference and market demand. Patients find them less uncomfortable.

Combination of multiple markers for detection: Newer tests are able to detect H. pylori as well as evaluate inflammation and function of stomach cells using biomarkers, providing crucial information to guide treatment decisions.

Miniaturization of devices: Portable battery-powered analyzers can perform point-of-care urea breath testing, increasing access in remote locations. Home-use kits may become available.

Market Opportunities

Emerging economies: Countries in Asia Pacific, Latin America, Africa and Eastern Europe with high H. pylori rates represent major opportunities for market players for both reagents and devices.

Screenings guidelines expansion: Widening of recommendations to include more groups such as diabetics for regular screenings can support market volumes.

Incorporation of AI: Integration of artificial intelligence and machine learning into breath testing analyzers could automate interpretation of results for faster reporting without human intervention.

Impact of COVID-19 on Urea Breath Test Market
The outbreak of the COVID-19 pandemic has significantly impacted the growth of the urea breath test market. Various factors such as lockdowns, travel restrictions, and supply chain disruptions have negatively influenced the market. The market experienced a decline in the number of urea breath tests conducted during the initial months of the pandemic due to the postponement of non-emergency procedures and diagnostics. However, with the evolution of the pandemic, healthcare facilities and diagnostic centers resumed urea breath tests with proper precautionary measures. This helped regain some lost momentum.

The pandemic highlighted the importance of early detection and management of Helicobacter pylori infection. This created greater awareness about urea breath testing among physicians and the general public. Telemedicine also emerged as an effective medium to evaluate and recommend urea breath tests to patients during the pandemic. Various stakeholders in the market adopted strategies like online ordering of testing kits and home sample collection to minimize patient visits to laboratories. This aided continued market growth.

Moving forward, factors like increased healthcare expenditure, emphasis on infectious disease control, expansion of telehealth, and initiatives to reduce diagnosis delays are expected to support the market in the post-pandemic period. However, uncertainties pertaining to future disease waves and economic challenges can hamper the forecasted growth trajectory to some extent. The market will need to focus on new product innovations, affordable solutions, and collaborative efforts with healthcare organizations to deal with long-term impacts.

In terms of value, North America holds the major share in the urea breath test market owing to the rise in Helicobacter pylori infections, developed healthcare infrastructure, favorable reimbursement policies, and presence of leading market players in the region. The Asia Pacific region is projected to witness the fastest growth during the forecast period. Factors such as improving access to diagnosis, increasing healthcare spending, growing clinical research, and rise in gastrointestinal disorders are fueling the demand for urea breath tests in Asia Pacific countries.

Get more insights on Urea Breath Test Market